📣 VC round data is live. Check it out!
- Public Comps
- Carvolix
Carvolix Valuation Multiples
Discover revenue and EBITDA valuation multiples for Carvolix and similar public comparables like Median Technologies, Kudan, SmartVest, Circus and more.
Carvolix Overview
About Carvolix
Carvolix SA specializes in the development of AI-based mini-robots and biomimetic implants designed to autonomously replace heart valves and treat strokes.
Founded
2018
HQ

Employees
67
Website
Financials (LTM)
EV
$237M
Valuation Multiples
Start free trialCarvolix Financials
Carvolix reported last 12-month revenue of $1M and negative EBITDA of ($22M).
In the same LTM period, Carvolix generated ($22M) in EBITDA losses and had net loss of ($26M).
Revenue (LTM)
Carvolix P&L
In the most recent fiscal year, Carvolix reported revenue of $5M and EBITDA of ($14M).
Carvolix is unprofitable as of last fiscal year, with gross margin of 21%, EBITDA margin of (290%), and net margin of (358%).
Financial data powered by Morningstar, Inc.
Carvolix Stock Performance
Carvolix has current market cap of $216M, and enterprise value of $237M.
Market Cap Evolution
Carvolix's stock price is $3.65.
Carvolix share price increased by 10.4% in the last 30 days, and by 119.8% in the last year.
Carvolix has an EPS (earnings per share) of $-0.29.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $237M | $216M | 0.7% | 10.4% | -11.4% | 119.8% | $-0.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCarvolix Valuation Multiples
Carvolix trades at 201.2x EV/Revenue multiple, and (11.0x) EV/EBITDA.
EV / Revenue (LTM)
Carvolix Financial Valuation Multiples
As of May 13, 2026, Carvolix has market cap of $216M and EV of $237M.
Carvolix has a P/E ratio of (8.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Carvolix Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Carvolix Margins & Growth Rates
Carvolix decreased revenue by 90% but EBITDA grew by 17% in the last fiscal year.
In the most recent fiscal year, Carvolix reported gross margin of 21%, EBITDA margin of (290%), and net margin of (358%).
Carvolix Margins
Carvolix Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Carvolix Operational KPIs
Carvolix's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Carvolix's Rule of 40 is (844%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Carvolix's Rule of X is (222%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Carvolix Competitors
Carvolix competitors include Median Technologies, Kudan, SmartVest, Circus, MEZOO, Quantum-Si, OraSure, Onward Medical, RxSight and Utah Medical.
Most Carvolix public comparables operate across Medical Devices, Autonomous AI & Robotics, HealthTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 8.0x | 7.7x | (11.9x) | (11.9x) | |||
| 56.5x | 27.8x | (39.5x) | — | |||
| 3.3x | 3.0x | 15.1x | 13.1x | |||
| 778.8x | 10.1x | (16.7x) | (13.5x) | |||
| — | 29.3x | — | — | |||
| 33.7x | 42.7x | (1.0x) | (1.0x) | |||
| 0.3x | 0.3x | (1.0x) | (1.0x) | |||
| 28.0x | 17.4x | (3.7x) | (3.2x) | |||
This data is available for Pro users. Sign up to see all Carvolix competitors and their valuation data. Start Free Trial | ||||||
Carvolix M&A Activity
Carvolix has acquired 2 companies to date.
Last acquisition by Carvolix was on December 19th 2025. Carvolix acquired Artedrone for $12M (EV/Revenue multiple of ).
Latest Acquisitions by Carvolix
| Description | Artedrone is a medtech company creating autonomous micro-robotic systems for mechanical thrombectomy in stroke treatment. | Caranx Medical is a medtech company building surgical robots integrating imaging, AI, and robotics. Its platforms enhance precision in minimally invasive procedures. |
| HQ Country | ||
| HQ City | — | — |
| Deal Date | 19 Dec 2025 | 19 Dec 2025 |
| Valuation | $12M | $18M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Carvolix acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Carvolix
| When was Carvolix founded? | Carvolix was founded in 2018. |
| Where is Carvolix headquartered? | Carvolix is headquartered in France. |
| How many employees does Carvolix have? | As of today, Carvolix has over 67 employees. |
| Is Carvolix publicly listed? | Yes, Carvolix is a public company listed on Euronext Paris. |
| What is the stock symbol of Carvolix? | Carvolix trades under CVX ticker. |
| When did Carvolix go public? | Carvolix went public in 2021. |
| Who are competitors of Carvolix? | Carvolix main competitors include Median Technologies, Kudan, SmartVest, Circus, MEZOO, Quantum-Si, OraSure, Onward Medical, RxSight, Utah Medical. |
| What is the current market cap of Carvolix? | Carvolix's current market cap is $216M. |
| What is the current revenue of Carvolix? | Carvolix's last 12 months revenue is $1M. |
| What is the current revenue growth of Carvolix? | Carvolix revenue growth (NTM/LTM) is 441%. |
| What is the current EV/Revenue multiple of Carvolix? | Current revenue multiple of Carvolix is 201.2x. |
| Is Carvolix profitable? | No, Carvolix is not profitable. |
| What is the current EBITDA of Carvolix? | Carvolix has negative EBITDA and is not profitable. |
| What is Carvolix's EBITDA margin? | Carvolix's last 12 months EBITDA margin is (1832%). |
| What is the current EV/EBITDA multiple of Carvolix? | Current EBITDA multiple of Carvolix is (11.0x). |
| What is the current FCF of Carvolix? | Carvolix's last 12 months FCF is ($23M). |
| What is Carvolix's FCF margin? | Carvolix's last 12 months FCF margin is (1990%). |
| What is the current EV/FCF multiple of Carvolix? | Current FCF multiple of Carvolix is (10.1x). |
| How many companies Carvolix has acquired to date? | As of May 2026, Carvolix has acquired 2 companies. |
| What was the largest acquisition by Carvolix? | $18M acquisition of Caranx Medical on 19th December 2025 was the largest M&A Carvolix has done to date. |
| What companies Carvolix acquired? | Carvolix acquired Caranx Medical and Artedrone. |
| In how many companies Carvolix has invested to date? | Carvolix hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Carvolix
Lists including Carvolix
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
